1. |
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1204-1222.
|
2. |
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1223-1249.
|
3. |
GBD 2019 Risk Factors Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: A comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1160-1203.
|
4. |
Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2019, 394(10204): 1145-1158.
|
5. |
Nambiar L, LeWinter MM, VanBuren PC, et al. Decade-long temporal trends in U. S. hypertension-related cardiovascular mortality. J Am Coll Cardiol, 2020, 75(20): 2644-2646.
|
6. |
李立明, 饶克勤, 孔灵芝, 等. 中国居民2002年营养与健康状况调查. 中华流行病学杂志, 2005, 26(7): 478-484.
|
7. |
赵丽云, 于冬梅, 付萍, 等. 2010—2012年中国18岁及以上成人高血压患病率—基于汞柱式和转换电子血压值. 卫生研究, 2018, 47(1): 7-12.
|
8. |
Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: Results from the China hypertension survey, 2012-2015. Circulation, 2018, 137(22): 2344-2356.
|
9. |
张梅, 吴静, 张笑, 等. 2018年中国成年居民高血压患病与控制状况研究. 中华流行病学杂志, 2021, 42(10): 1780-1789.
|
10. |
Li Y, Yang L, Wang L, et al. Burden of hypertension in China: A nationally representative survey of 174, 621 adults. Int J Cardiol, 2017, 227: 516-523.
|
11. |
Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: Data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet, 2017, 390(10112): 2549-2558.
|
12. |
Campbell NRC, Zhang XH. Hypertension in China: Time to transition from knowing the problem to implementing the solution. Circulation, 2018, 137(22): 2357-2359.
|
13. |
Tao S, Wu X, Duan X, et al. Hypertension prevalence and status of awareness, treatment and control in China. Chin Med J (Engl), 1995, 108(7): 483-489.
|
14. |
Gu D, Chen J, Wu X, et al. Prehypertension and risk of cardiovascular disease in Chinese adults. J Hypertens, 2009, 27(4): 721-729.
|
15. |
Gu D, Reynolds K, Wu X, et al. Prevalence, awareness, treatment, and control of hypertension in china. Hypertension, 2002, 40(6): 920-927.
|
16. |
Wu Y, Huxley R, Li L, et al. Prevalence, awareness, treatment, and control of hypertension in China: Data from the China National Nutrition and Health Survey 2002. Circulation, 2008, 118(25): 2679-2686.
|
17. |
Li W, Gu H, Teo KK, et al. Hypertension prevalence, awareness, treatment, and control in 115 rural and urban communities involving 47 000 people from China. J Hypertens, 2016, 34(1): 39-46.
|
18. |
Wang W, Zhang M, Xu CD, et al. Hypertension prevalence, awareness, treatment, and control and their associated socioeconomic factors in China: A spatial analysis of a national representative survey. Biomed Environ Sci, 2021, 34(12): 937-951.
|
19. |
Li Y, Teng D, Shi X, et al. Changes in the prevalence of obesity and hypertension and demographic risk factor profiles in China over 10 years: Two national cross-sectional surveys. Lancet Reg Health West Pac, 2021, 15: 100227.
|
20. |
Ma Z, Hummel SL, Sun N, et al. From salt to hypertension, what is missed? J Clin Hypertens (Greenwich), 2021, 23(12): 2033-2041.
|
21. |
Li Z, Cao L, Zhou Z, et al. Factors influencing the progression from prehypertension to hypertension among Chinese middle-aged and older adults: A 2-year longitudinal study. BMC Public Health, 2023, 23(1): 339.
|
22. |
孙丽艳. 寒冷暴露与高血压的关系. 中华地方病学杂志, 2015, 34(8): 621-624.
|
23. |
房玥晖, 何宇纳, 白国银, 等. 2012年中国20~79岁男性饮酒现状分析. 中华流行病学杂志, 2018, 39(3): 280-285.
|
24. |
Chen K, Shen Z, Gu W, et al. Prevalence of obesity and associated complications in China: A cross-sectional, real-world study in 15.8 million adults. Diabetes Obes Metab, 2023, 25(11): 3390-3399.
|
25. |
于冬梅, 何宇纳, 房红芸, 等. 2010-2012年中国成年居民食盐摄入状况. 中华预防医学杂志, 2016, 50(3): 217-220.
|
26. |
Wang M, Luo X, Xu S, et al. Trends in smoking prevalence and implication for chronic diseases in China: Serial national cross-sectional surveys from 2003 to 2013. Lancet Respir Med, 2019, 7(1): 35-45.
|
27. |
Millwood IY, Walters RG, Mei XW, et al. Conventional and genetic evidence on alcohol and vascular disease aetiology: A prospective study of 500 000 men and women in China. Lancet, 2019, 393(10183): 1831-1842.
|
28. |
Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. Circulation, 2016, 134(6): 441-450.
|
29. |
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet, 2021, 398(10304): 957-980.
|
30. |
Egan BM, Stevens-Fabry S. Prehypertensio—Revalence, health risks, and management strategies. Nat Rev Cardiol, 2015, 12(5): 289-300.
|
31. |
Guo J, Zhu YC, Chen YP, et al. The dynamics of hypertension prevalence, awareness, treatment, control and associated factors in Chinese adults: Results from CHNS 1991-2011. J Hypertens, 2015, 33(8): 1688-1696.
|
32. |
Wu X, Liang D, Sun J, et al. Association between sex-specific serum gamma-glutamyltransferase and incidence of hypertension in a Chinese population without metabolic syndrome: A prospective observational study. Front Cardiovasc Med, 2021, 8: 644044.
|
33. |
Dorjgochoo T, Shu XO, Zhang X, et al. Relation of blood pressure components and categories and all-cause, stroke and coronary heart disease mortality in urban Chinese women: A population-based prospective study. J Hypertens, 2009, 27(3): 468-475.
|
34. |
Cai C, Liu F C, Li JX, et al. Effects of the total physical activity and its changes on incidence, progression, and remission of hypertension. J Geriatr Cardiol, 2021, 18(3): 175-184.
|
35. |
Liu Q, Huang K, Liang F, et al. Long-term exposure to fine particulate matter modifies the association between physical activity and hypertension incidence. J Sport Health Sci, 2022, 11(6): 708-715.
|
36. |
Yao F, Liu W, Zhao R, et al. BMI modified the association of current smoking with the incidence of hypertension in Chinese population: A 22-year cohort study. BMC Public Health, 2020, 20(1): 295.
|
37. |
韩雪玉, 齐玥, 赵冬, 等. 中国人群长期血压变化与心血管病发病风险关系的前瞻性队列研究. 中华心血管病杂志, 2018, 46(9): 695-670.
|
38. |
Lu YK, Dong J, Sun Y, et al. Gender-specific predictive ability for the risk of hypertension incidence related to baseline level or trajectories of adiposity indices: A cohort study of functional community. Int J Obes (Lond), 2022, 46(5): 1036-1043.
|
39. |
Liao CT, Wu PC, Shih JC, et al. Higher hypertension prevalence, lower incidence, and aggressive treatment with decreasing mortality, cardiovascular, and cerebrovascular incidence in Taiwan from 2005 to 2010: A 2 population-based cohorts study. Medicine (Baltimore), 2020, 99(39): e22437.
|